Systemic Lupus Erythematosus

Immunology·MeSH: Lupus Erythematosus, Systemic

Prevalence

72.0 / 100K

Incidence

5.1 / 100K/yr

77 drugs in development·40 companies·54 clinical trials

Drug Pipeline by Phase

Phase 3(17)

Drug	Company
cenerimod	Innovation Pharmaceuticals Inc. (IPIX)
dapirolizumab pegol	GT Biopharma, Inc. (GTBP)
dapirolizumab pegol	BIOGEN INC. (BIIB)
dapirolizumab pegol	POINT Biopharma Global Inc. (PNT)
Dapirolizumab Pegol	NEKTAR THERAPEUTICS (NKTR)
descartes-08	Cartesian Therapeutics, Inc. (RNAC)
dnth212	Dianthus Therapeutics, Inc. /DE/ (DNTH)
dzp	POINT Biopharma Global Inc. (PNT)
dzp	GT Biopharma, Inc. (GTBP)
ESK-001	ALUMIS INC. (ALMS)
Fludarabine	BRISTOL MYERS SQUIBB CO (BMY)
Ianalumab	Novartis AG (NVS)
ianalumab s.c. q12w	Novartis AG (NVS)
Medi-546	ASTRAZENECA PLC (AZN)
sar448501	Sanofi (SNYNF)
Tocilizumab	BRISTOL MYERS SQUIBB CO (BMY)
UCAR-T cells	Filana Therapeutics Inc. (FLNA)

Phase 2(27)

Drug	Company
afimetoran	BRISTOL MYERS SQUIBB CO (BMY)
alpn-101	ALPINE IMMUNE SCIENCES, INC. (ALPN)
anifrolumab	Valneva SE (VALN)
AUCATZYL/obe-cel	Autolus Therapeutics plc (AUTL)
AZD5492	ASTRAZENECA PLC (AZN)
belimumab 10mg/kg	GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
cc-97540	Juno Therapeutics, Inc. (JUNO)
CC-97540	BRISTOL MYERS SQUIBB CO (BMY)
cd19	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
cfz533	Novartis AG (NVS)
glpg3667	Galapagos NV (GLPG)
GLPG3667	Galapagos NV (GLPG)
iberdomide	CELGENE CORP /DE/ (CELG)
imvotamab	IGM Biosciences, Inc. (IGMS)
inebilizumab	AMGEN INC (AMGN)
mb-cart19.1	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
MK-1045	Merck & Co., Inc. (MRK)
obecabtagene autoleucel	Autolus Therapeutics plc (AUTL)
prv-3279	Sanofi (SNY)
prv-3279	PROVENTION BIO, INC. (PBI)
prv-3279	Sanofi (SNYNF)
PRV-3279	MACROGENICS INC (MGNX)
rese-cel	Cabaletta Bio, Inc. (CABA)
sar441344 iv	Sanofi (SNYNF)
sar441344 iv	Sanofi (SNY)
sar441344 sc	Sanofi (SNY)
sar441344 sc	Sanofi (SNYNF)

Phase 1(18)

Drug	Company
abbv-519	AbbVie Inc. (ABBV)
ALLO-329	Allogene Therapeutics, Inc. (ALLO)
blinatumomab	AMGEN INC (AMGN)
cenerimod	Viatris Inc (VTRS)
cnty-101	Century Therapeutics, Inc. (IPSC)
cnty-308	Century Therapeutics, Inc. (IPSC)
cnty-341	Century Therapeutics, Inc. (IPSC)
cnty-813	Century Therapeutics, Inc. (IPSC)
il-2	Century Therapeutics, Inc. (IPSC)
Litifilimab	BIOGEN INC. (BIIB)
LUCAR-G79D T cells	Legend Biotech Corp (LEGN)
lymphodepleting chemotherapy	Century Therapeutics, Inc. (IPSC)
pit565	Novartis AG (NVS)
pit565	Novartis AG (NVS)
prula-cel	Adicet Bio, Inc. (ACET)
pt101	Pandion Therapeutics, Inc. (PAND)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)
sar448501	Sanofi (SNY)

Preclinical(4)

Drug	Company
eb201	Estrella Immunopharma Inc. (ESLA)
gri-0803	GRI Bio, Inc. (GRI)
inb-619	IN8BIO, INC. (INAB)
IRF5 program	ALUMIS INC. (ALMS)

Phase 1/Phase 2(6)

Drug	Company
alpn-303	ALPINE IMMUNE SCIENCES, INC. (ALPN)
anti-cd19 car t cell therapy	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
gc012f	SQZ Biotechnologies Co (SQZB)
ytb323	Novartis AG (NVS)
YTB323	Novartis AG (NVS)
zugo-cel	CRISPR Therapeutics AG (CRSP)

Phase 4(5)

BioSniper tracks 77 drugs in development for Systemic Lupus Erythematosus across 40 companies.

There are 54 clinical trials targeting Systemic Lupus Erythematosus tracked by BioSniper.

The estimated prevalence of Systemic Lupus Erythematosus is approximately 72.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.